Advana Science Release: New Biotechnology Scientific Discoveries in Cognitive Health Ready for Nutraceutical Application

KIRKLAND, Wash.--(BUSINESS WIRE)--Advana Science will unveil new biotechnology scientific discoveries in beta amyloid plaque reduction linked to major degenerative diseases, including Alzheimer's disease and Type 2 diabetes for nutraceutical application. This safe, natural compound offers unprecedented opportunities for nutraceutical companies seeking science-based solutions for consumers. Peter Leighton, CEO, Advana Science will present these new developments at the leading ingredient supplier meeting; Supply Side West in Las Vegas on October 24th at booth# 10056 at 1:30 pm PT.